Predictive value of interferon-γ ELISPOT assay in HIV 1-infected patients in an intermediate tuberculosis-endemic area

AIDS Research and Human Retroviruses

Volumn 28, Issue 9, 2012, Pages 838-843

  Kim, Youn Jeong ^a   Kim, Sang Il ^a   Kim, Yang Ree ^a   Wie, Seong Heon ^a   Park, Yeon Joon ^b   Kang, Moon Won ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TUBERCULOSIS;

EID: 84865527965     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0360     Document Type: Article

References (31)

1. World Health Organization. AIDS epidemic update. http://apps.who.int/ ghodata/. Accessed 31 March, 2011.
2. Hill PC, Brookes RH, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004;38(7):966-973. (Pubitemid 38457204)
3. Lawn SD, Bangani N, Vogt M, et al. Utility of interferongamma ELISPOT assay responses in highly tuberculosisexposed patients with advanced HIV infection in South Africa. BMC Infect Dis 2007;7:99.
4. Cattamanchi A, Smith R, Steingart KR, et al. Interferongamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: A systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011;56(3):230-238.
5. Hong YP, Kim SJ, Lew WJ, Lee EK, and Han YC: The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998;2(1):27-36. (Pubitemid 28108939)
6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. J Assoc Physicians India 2006;54:219-234.
7. Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161(4 Pt 1):1376-1395.
8. Lee LN, Chou CH, Wang JY, et al. Enzyme-linked immunospot assay for interferon-gamma in the diagnosis of tuberculous pleurisy. Clin Microbiol Infect 2009;15(2):173-179.
9. Kang YA, Lee HW, Hwang SS, et al. Usefulness of wholeblood interferon-gamma assay and interferon-gamma enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis. Chest 2007;132(3):959-965.
10. Pai M, Riley LW, and Colford JM Jr: Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4(12):761-776.
11. Kim SH, Cho OH, Park SJ, et al. Diagnosis of abdominal tuberculosis by T-cell-based assays on peripheral blood and peritoneal fluid mononuclear cells. J Infect 2009;59(6):409-415.
12. Narain JP and Lo YR: Epidemiology of HIV-TB in Asia. Indian J Med Res 2004;120(4):277-289. (Pubitemid 39504468)
13. Furin JJ and Johnson JL: Recent advances in the diagnosis and management of tuberculosis. Curr Opin Pulm Med 2005;11(3):189-194. (Pubitemid 40577167)
14. Richeldi L: An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006;174(7):736-742. (Pubitemid 44511654)
15. Cleveland JL, Robison VA, and Panlilio AL: Tuberculosis epidemiology, diagnosis and infection control recommendations for dental settings: An update on the Centers for Disease Control and Prevention guidelines. J Am Dent Assoc 2009;140(9):1092-1099.
16. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, and Masur H: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4):1-207; quiz CE201-204.
17. Bai GH, Park YK, Choi YW, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11(5):571-576.
18. Kim EY, Lim JE, Jung JY, et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009;9:207.
19. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221-247.
20. Nahid P and Daley CL: Prevention of tuberculosis in HIVinfected patients. Curr Opin Infect Dis 2006;19(2):189-193.
21. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49(RR-6):1-51.
22. Rolinck-Werninghaus C, Magdorf K, Stark K, et al. The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection. Eur J Pediatr 2003;162(7-8):534-536. (Pubitemid 36904287)
23. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a wholeblood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009;48(7):954-962.
24. Hammond AS, McConkey SJ, Hill PC, et al. Mycobacterial T cell responses in HIV-infected patients with advanced immunosuppression. J Infect Dis 2008;197(2):295-299. (Pubitemid 351263451)
25. Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigenspecific immune responses can be detected using enzymelinked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007;150(2):238-244. (Pubitemid 47609557)
26. Nagai H: Factors for the onset of and the exacerbation of tuberculosis. 5. The infection and prognosis of tuberculosis among patients with immunodeficiency, especially HIV-infected patients. Kekkaku 1999;74(10):753-758. (Pubitemid 29518708)
27. Moreno S, Jarrin I, Iribarren JA, et al. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung Dis 2008;12(12):1393-1400.
28. Karam F, Mbow F, Fletcher H, et al. Sensitivity of IFNgamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/ AIDS progression. PLoS One 2008;3(1):e1441.
29. CattamanchiA, Smith R, SteingartKR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: A systematic review and metaanalysis. J Acquir Immune Defic Syndr 2011;56(3):230-238.
30. Leidl L, Mayanja-Kizza H, Sotgiu G, et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4 + T-cells in HIV infection. Eur Respir J 2010;35(3):619-626.
31. Lawn SD, Myer L, Bekker LG, and Wood R: Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: Impact on treatment outcomes and implications for tuberculosis control. AIDS 2006;20(12):1605-1612. (Pubitemid 44162402)